IGT Congressional Letter and Statement on the Re-Introduction of the MVP Act (H.R. 2666)
Today, the Institute for Gene Therapies (IGT) sent a letter to Congress applauding Representatives Brett Guthrie (R-KY), Anna Eshoo...
IGT Congressional Letter and Statement on the Re-Introduction of the MVP Act (H.R. 2666)
Perspective: Advancing Hope for Andrew and Countless Others
Our Healthcare Policies Must Account for the True Value of Transformative Gene Therapies
Congressional Briefing: Realizing the Promise of Gene Therapy through Science & Policy
ICYMI: Cure Sickle Cell Disease by 2030?
A Bold Goal to Cure Sickle Cell Disease by 2030
IGT Comments on CMS Fiscal Year 2023 Medicare Inpatient Prospective Payment Systems Proposed Rule
New Resource: Understanding the Complexity of Gene Therapy Science & Manufacturing